In the present study, we analyzed the histological, immunohistochemical, microRNA, and clinicopathological status in tumors initially diagnosed as malignant rhabdoid ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 56-year-old man presented to the ED with 3 months of ...

A triple-drug regimen combining two immunotherapy agents with radiation before surgery appears to activate immune defenses against aggressive soft tissue sarcomas, based on early phase II data ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...

Keytruda is showing benefit to some patients with sarcoma, according to interim results from a phase 2 trial. According to interim results from the phase 2 SARC-028 trial, Keytruda (pembrolizumab) ...

An expert writes about his experience as a sarcoma medical oncologist and how the field may progress with several therapies in the pipeline. As a sarcoma medical oncologist, the No. 1 question I am ...